Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 6.5% – Here’s What Happened

Posted by George Bondi on Jun 16th, 2026

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) shares were up 6.5% on Tuesday . The company traded as high as $12.82 and last traded at $12.8710. Approximately 915,686 shares traded hands during mid-day trading, a decline of 21% from the average daily volume of 1,164,116 shares. The stock had previously closed at $12.08.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Chardan Capital upped their target price on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. HC Wainwright upped their target price on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, April 21st. Citigroup upped their target price on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Finally, Royal Bank Of Canada dropped their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.80.

Check Out Our Latest Research Report on EYPT

Eyepoint Pharmaceuticals Price Performance

The stock’s 50-day moving average is $13.29 and its two-hundred day moving average is $14.68. The stock has a market cap of $1.09 billion, a P/E ratio of -3.70 and a beta of 1.72.

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.35 million. On average, analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -3.09 EPS for the current fiscal year.

Insider Transactions at Eyepoint Pharmaceuticals

In related news, insider Ramiro Ribeiro sold 2,437 shares of the company’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $15.00, for a total transaction of $36,555.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 5.13% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Cyndeo Wealth Partners LLC raised its stake in Eyepoint Pharmaceuticals by 3.4% during the fourth quarter. Cyndeo Wealth Partners LLC now owns 22,990 shares of the company’s stock valued at $420,000 after purchasing an additional 760 shares in the last quarter. California State Teachers Retirement System raised its stake in Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after purchasing an additional 794 shares in the last quarter. RWC Asset Management LLP raised its stake in Eyepoint Pharmaceuticals by 6.4% during the fourth quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock valued at $315,000 after purchasing an additional 1,040 shares in the last quarter. MCF Advisors LLC raised its stake in Eyepoint Pharmaceuticals by 8.3% during the fourth quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock valued at $273,000 after purchasing an additional 1,149 shares in the last quarter. Finally, Raymond James Financial Inc. raised its stake in shares of Eyepoint Pharmaceuticals by 11.0% in the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after acquiring an additional 1,177 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

(Get Free Report)

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.